DEFA14A ·Filed Mar 11, 2026

JNJ

JOHNSON & JOHNSON
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago SEC0000200406-26-000065
Proxy solicitation materials
Actionable Insight • Neutral

This is a standard, non-eventful proxy filing. Traders should expect no immediate market reaction. Monitor for any unexpected proposals in the full proxy, though none are indicated here.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
JNJ ▼ -8.11% at T+60d
NEUTRAL call ✗ call lost -8.11% · α vs SPY -19.63% · entry $242.95 → $223.24
Entry anchored
Mar 10, 03:59 PM ET
via exchange tick
T+1d
-0.35%
call -0.35% · α +1.13%
$242.10
settled 7mo ago
T+5d
-2.37%
call -2.37% · α -0.18%
$237.20
settled 7mo ago
T+20d
-0.71%
call -0.71% · α -1.24%
$241.22
settled 6mo ago
T+60d
-8.11%
call -8.11% · α -19.63%
$223.24
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Johnson & Johnson filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting. The filing is routine and filed by the company (registrant), disclosing items such as director elections and executive compensation. No activist campaign or contested vote is indicated. Market data shows analyst sentiment is mixed (59% bullish), with minimal recent insider selling.

Key Facts

  • Filing is a routine DEFA14A proxy statement filed by Johnson & Johnson.
  • Filed as 'Definitive Proxy Statement', indicating standard disclosure for an upcoming shareholder vote.
  • Items likely include election of directors, executive compensation, and other standard corporate governance matters.
  • No indication of a dissident party or activist campaign; this is a standard management solicitation.
  • Recent insider activity shows only a minor sell transaction by a Congressman.

Financial Impact

No direct financial impact from the filing itself.

Risk Factors

  • The actual proxy document (not fully provided) could contain unexpected items, though the filing type and headers suggest it's routine.

Market Snapshot

Exchange
NYSE
Analyst Consensus
59% bullish (32 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0000200406-26-000065
Document: 0000200406-26-000065-index-headers.html0000200406-26-000065
Document: 0000200406-26-000065-index.html0000200406-26-000065
Document: 0000200406-26-000065.txt0000200406-26-000065
16 reports for JNJ
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+60▲ +13.24%May 13, 2026
Filters
Rows
Reports for JNJ — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
Court Ruling
NEUTRAL ★ 1/10
$267.08 $267.28▲ +0.07%▲ +0.73%$256.14 (−4.10%)
Aug 18, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$273.41 $270.00▼ −1.25%▼ −0.86%$256.14 (−6.32%)
Aug 14, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$260.35 $270.24▲ +3.80%▲ +5.17%$256.14 (−1.62%)
Aug 7, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$261.81 $262.37▲ +0.21%▲ +0.26%$256.14 (−2.17%)
Aug 7, 2026
8w ago
Court Ruling
BEARISH ★ 4/10
$259.24 $260.35▼ −0.43%▼ −0.03%$256.14 (+1.20%)
Aug 4, 2026
8w ago
8-K
NEUTRAL ★ 2/10
$254.93 $259.80▲ +1.91%▲ +2.01%$256.14 (+0.47%)
Jul 22, 2026
10w ago
Court Ruling
BEARISH ★ 7/10
$255.63 $265.53▼ −3.87%▼ −6.27%$256.14 (−0.20%)
Jul 15, 2026
11w ago
8-K
BULLISH ★ 6/10
$247.02 $255.63▲ +3.49%▲ +4.47%$256.14 (+3.69%)
May 20, 2026
19w ago
Court Ruling
NEUTRAL ★ 1/10
$229.12 $231.29▲ +0.95%▼ −0.29%$256.14 (+11.79%)
May 13, 2026
20w ago
ANALYST-UPGRADE
BULLISH ★ 3/10
$230.79 $231.58▲ +0.34%▲ +1.06%$256.14 (+10.98%)
Showing 10 of 16

US Market Status

Market Open — Closes in 3h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access